재발 완화형 다발성 경화증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 연평균 4.8%의 CAGR로 58억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 맞춤형 의료의 채택 증가, 바이오마커 연구에 대한 관심 증가, 새로운 치료 접근법에 대한 투자 증가, 질병 관리에 AI 활용 확대, 혁신적 치료에 대한 규제 지원 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 유전자 및 세포 치료의 출현, 경구용 질병 변형 치료로의 전환, 혈액뇌관문 약물전달 시스템의 발전, 질병 변형 치료의 발전, 차세대 단클론항체 개발 등이 있습니다.
맞춤형 의료의 채택 확대가 재발 완화형 다발성 경화증(RRMS) 시장의 성장을 견인할 것으로 예상됩니다. 맞춤의료는 개인의 유전적, 환경적, 생활습관적 요인에 따라 치료와 요법을 맞춤화하여 의료 결과를 최적화하는 것입니다. 이러한 접근법은 유전자 변이 및 바이오마커를 정확하게 식별하여 보다 효과적인 치료로 이어질 수 있는 유전체 염기서열 분석의 발전으로 인해 더욱 힘을 얻고 있으며, RRMS는 맞춤형 치료가 질병의 진행, 증상의 심각성, 치료 효과의 개인차에 어떻게 대응하여 궁극적으로 환자의 결과를 개선할 수 있는지를 보여줍니다. 결과를 개선하는지를 보여줌으로써 맞춤의료의 중요성을 강조하고 있습니다. 예를 들어, 2024년 2월 미국 맞춤형 의료를 옹호하는 미국 기반 단체인 맞춤형 의료 연합은 미국 식품의약국(FDA)이 희귀질환 환자를 위한 16개의 새로운 맞춤형 치료제를 승인했다고 보고했습니다. 그 결과, 맞춤형 의료의 채택 확대가 RRMS 시장의 성장을 견인하고 있습니다.
재발 완화형 다발성 경화증 시장의 주요 기업들은 치료 효과 향상, 환자 결과 개선, RRMS 표준 치료의 재정의 등을 목표로 획기적인 블록버스터 치료제와 같은 혁신적인 치료 접근법을 개발하고 있습니다. 획기적 블록버스터 치료는 의료를 크게 발전시키는 매우 효과적인 치료법을 의미하며, 종종 미충족 수요를 충족시키거나 기존 치료법에 비해 우수한 치료 결과를 가져오는 경우가 많습니다. 예를 들어, 2024년 2월 인도 제약사 로슈(Roche Products(India)는 신경계 포트폴리오를 강화하고 인도 환자의 미충족 의료 수요를 충족시키기 위해 다발성 경화증(MS) 치료제인 오클레바스(Ocrevus, 오크레리주맙)를 도입했습니다. 오클레바스는 다발성 경화증 진행에 관여하는 CD20 양성 B세포를 표적으로 삼아 재발을 억제하고 장애의 진행을 늦추는 것을 목표로 하며, B세포를 선택적으로 고갈시키는 독특한 작용 기전을 통해 질병 경과를 교정하고 환자의 장기적 예후를 개선합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 재발 완화형 다발성 경화증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 재발 완화형 다발성 경화증 시장 : 성장률 분석
- 세계의 재발 완화형 다발성 경화증 시장 실적 : 규모와 성장, 2019-2024
- 세계의 재발 완화형 다발성 경화증 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 재발 완화형 다발성 경화증 전체 시장(TAM)
제6장 시장 세분화
- 세계의 재발 완화형 다발성 경화증 시장 약제 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 베타 인터페론
- 클라드리빈
- 디메틸 푸마르산염
- 핑골리모드
- 오자니모드
- 기타 약물 종류
- 세계의 재발 완화형 다발성 경화증 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 피하
- 정맥내
- 세계의 재발 완화형 다발성 경화증 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 면역조절제
- NrF2 활성화제
- 인터페론
- 기타 치료법
- 세계의 재발 완화형 다발성 경화증 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 클리닉
- 기타 최종사용자
- 세계의 재발 완화형 다발성 경화증 시장, 베타 인터페론 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 인터페론 β-1a
- 인터페론 베타 1b
- 세계의 재발 완화형 다발성 경화증 시장 클라드리빈 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 클라드리빈
- 주사용 클라드리빈
- 세계의 재발 완화형 다발성 경화증 시장 디메틸 푸마르산 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 테크피데라
- 브메리티
- 세계의 재발 완화형 다발성 경화증 시장 핀골리모드 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 길레니아 핀골리모드
- 제네릭 핀골리모드
- 세계의 재발 완화형 다발성 경화증 시장 오자니모드 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 제포시아
- 세계의 재발 완화형 다발성 경화증 시장, 기타 약물 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 나탈리주맙
- 알렘투주맙
- 오크레리주맙
- 시포니모드
- 테리플루노마이드
제7장 지역별·국가별 분석
- 세계의 재발 완화형 다발성 경화증 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 재발 완화형 다발성 경화증 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 재발 완화형 다발성 경화증 시장 : 경쟁 구도
- 재발 완화형 다발성 경화증 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Novartis AG
- GSK plc
- Eli Lilly and Company
- Merck KGaA
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Biogen Inc.
- Eisai Co. Ltd.
- Genentech Inc.
- Hikma Pharmaceuticals LLC
- Glenmark Pharmaceuticals Limited
- CinnaGen Co
- Zenas BioPharma Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 재발 완화형 다발성 경화증 시장 2029 : 새로운 기회를 제공하는 국가
- 재발 완화형 다발성 경화증 시장 2029 : 새로운 기회를 제공하는 부문
- 재발 완화형 다발성 경화증 시장 2029 : 성장 전략
제36장 부록
ksm
Relapsing-remitting multiple sclerosis (RRMS) is a chronic neurological condition characterized by recurring episodes of symptoms (relapses) followed by periods of partial or complete recovery (remissions). It occurs when the immune system attacks the myelin sheath, impairing nerve signal transmission in the central nervous system.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main drug types used to treat relapsing-remitting multiple sclerosis include beta-interferon, cladribine, dimethyl fumarate, fingolimod, ozanimod, and others. Beta-interferon helps regulate the immune system to reduce inflammation and slow damage to the nervous system. These drugs are administered through various routes, including subcutaneous and intravenous injections. Treatment options include immunomodulating drugs, NrF2 activators, interferons, and others, and are commonly used by healthcare providers in hospitals and clinics.
The relapsing-remitting multiple sclerosis market research report is one of a series of new reports from The Business Research Company that provides relapsing-remitting multiple sclerosis market statistics, including the relapsing-remitting multiple sclerosis industry global market size, regional shares, competitors with the relapsing-remitting multiple sclerosis market share, detailed relapsing-remitting multiple sclerosis market segments, market trends, and opportunities, and any further data you may need to thrive in the relapsing-remitting multiple sclerosis industry. This relapsing-remitting multiple sclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The relapsing-remitting multiple sclerosis market size has grown strongly in recent years. It will grow from$4.58 billion in 2024 to $4.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to the increasing prevalence of multiple sclerosis, greater awareness and early diagnosis, the expansion of healthcare infrastructure, rising government funding for neurological disorders, and improved patient access to treatment.
The relapsing-remitting multiple sclerosis market size is expected to see strong growth in the next few years. It will grow to$5.81 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth during the forecast period can be attributed to the rising adoption of personalized medicine, increased focus on biomarker research, growing investment in novel therapeutic approaches, expanded use of AI in disease management, and regulatory support for innovative treatments. Key trends expected during this period include the emergence of gene and cell therapies, a shift towards oral disease-modifying therapies, advancements in blood-brain barrier drug delivery systems, progress in disease-modifying therapies, and the development of next-generation monoclonal antibodies.
The growing adoption of personalized medicine is expected to drive the expansion of the relapsing-remitting multiple sclerosis (RRMS) market. Personalized medicine tailors treatments and therapies to an individual's genetic, environmental, and lifestyle factors, optimizing healthcare outcomes. This approach is gaining traction due to advancements in genomic sequencing, which enable the precise identification of genetic variations and biomarkers, leading to more targeted and effective treatments. RRMS emphasizes the importance of personalized medicine by demonstrating how tailored treatments can address individual variations in disease progression, symptom severity, and treatment response, ultimately improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization advocating for personalized medicine, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from just 6 in 2022. As a result, the growing adoption of personalized medicine is fueling the growth of the RRMS market.
Leading companies in the relapsing-remitting multiple sclerosis market are developing innovative treatment approaches, such as breakthrough blockbuster therapies, to improve treatment efficacy, enhance patient outcomes, and redefine the standard of care for RRMS. Breakthrough blockbuster therapy refers to highly effective treatments that significantly advance medical care, often addressing unmet needs or providing superior outcomes compared to existing therapies. For instance, in February 2024, Roche Products (India) Pvt. Ltd., an India-based pharmaceutical company, introduced Ocrevus (Ocrelizumab), a groundbreaking treatment for multiple sclerosis (MS), to strengthen its neurology portfolio and meet the unmet medical needs of patients in India. Ocrevus targets CD20-positive B cells, which contribute to MS progression, aiming to reduce relapses and slow disability advancement. With a unique mechanism of action that selectively depletes B cells, Ocrevus helps modify the disease course and improve long-term patient outcomes.
In January 2025, Cycle Pharmaceuticals Ltd., a UK-based biopharmaceutical company, acquired Banner Life Sciences for an undisclosed sum. This acquisition allows Cycle Pharmaceuticals to expand its portfolio of treatments for neurological disorders, including multiple sclerosis, and strengthens its position in the U.S. pharmaceutical market. Banner Life Sciences, a U.S.-based company, offers BAFIERTAM as a treatment for relapsing forms of multiple sclerosis, including relapsing-remitting MS.
Major players in the relapsing-remitting multiple sclerosis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Hikma Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, CinnaGen Co, and Zenas BioPharma Inc.
North America was the largest region in the relapsing-remitting multiple sclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in relapsing-remitting multiple sclerosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the relapsing-remitting multiple sclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The relapsing-remitting multiple sclerosis market consists of revenues earned by entities by providing services such as disease-modifying therapies (DMTs), immunosuppressants, and symptom management solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The relapsing-remitting multiple sclerosis market also includes sales of pharmaceuticals, assistive devices, and diagnostic tools used in disease management and monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Relapsing-Remitting Multiple Sclerosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on relapsing-remitting multiple sclerosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for relapsing-remitting multiple sclerosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The relapsing-remitting multiple sclerosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Beta-Interferon; Cladribine; Dimethyl Fumarate; Fingolimod; Ozanimod; Other Drug Types
- 2) By Route Of Administration: Subcutaneous; Intravenous
- 3) By Treatment: Immunomodulating Drugs; NrF2 Activators; Interferons; Other Treatments
- 4) By End-User: Hospitals; Clinics; Other End-Users
- Subsegments:
- 1) By Beta-Interferon: Interferon Beta-1a; Interferon Beta-1b
- 2) By Cladribine: Oral Cladribine; Injectable Cladribine
- 3) By Dimethyl Fumarate: Tecfidera; Vumerity
- 4) By Fingolimod: Gilenya Fingolimod; Generic Fingolimod
- 5) By Ozanimod: Zeposia
- 6) By Other Drug Types: Natalizumab; Alemtuzumab; Ocrelizumab; Siponimod; Teriflunomide
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Relapsing-Remitting Multiple Sclerosis Market Characteristics
3. Relapsing-Remitting Multiple Sclerosis Market Trends And Strategies
4. Relapsing-Remitting Multiple Sclerosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Relapsing-Remitting Multiple Sclerosis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Relapsing-Remitting Multiple Sclerosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Relapsing-Remitting Multiple Sclerosis Market Growth Rate Analysis
- 5.4. Global Relapsing-Remitting Multiple Sclerosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Relapsing-Remitting Multiple Sclerosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Relapsing-Remitting Multiple Sclerosis Total Addressable Market (TAM)
6. Relapsing-Remitting Multiple Sclerosis Market Segmentation
- 6.1. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Beta-Interferon
- Cladribine
- Dimethyl Fumarate
- Fingolimod
- Ozanimod
- Other Drug Types
- 6.2. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Subcutaneous
- Intravenous
- 6.3. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunomodulating Drugs
- NrF2 Activators
- Interferons
- Other Treatments
- 6.4. Global Relapsing-Remitting Multiple Sclerosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Other End-Users
- 6.5. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Beta-Interferon, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Interferon Beta-1a
- Interferon Beta-1b
- 6.6. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Cladribine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Cladribine
- Injectable Cladribine
- 6.7. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Dimethyl Fumarate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tecfidera
- Vumerity
- 6.8. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Fingolimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gilenya Fingolimod
- Generic Fingolimod
- 6.9. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Ozanimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Zeposia
- 6.10. Global Relapsing-Remitting Multiple Sclerosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Natalizumab
- Alemtuzumab
- Ocrelizumab
- Siponimod
- Teriflunomide
7. Relapsing-Remitting Multiple Sclerosis Market Regional And Country Analysis
- 7.1. Global Relapsing-Remitting Multiple Sclerosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Relapsing-Remitting Multiple Sclerosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market
- 8.1. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Relapsing-Remitting Multiple Sclerosis Market
- 9.1. China Relapsing-Remitting Multiple Sclerosis Market Overview
- 9.2. China Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Relapsing-Remitting Multiple Sclerosis Market
- 10.1. India Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Relapsing-Remitting Multiple Sclerosis Market
- 11.1. Japan Relapsing-Remitting Multiple Sclerosis Market Overview
- 11.2. Japan Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Relapsing-Remitting Multiple Sclerosis Market
- 12.1. Australia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Relapsing-Remitting Multiple Sclerosis Market
- 13.1. Indonesia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Relapsing-Remitting Multiple Sclerosis Market
- 14.1. South Korea Relapsing-Remitting Multiple Sclerosis Market Overview
- 14.2. South Korea Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Relapsing-Remitting Multiple Sclerosis Market
- 15.1. Western Europe Relapsing-Remitting Multiple Sclerosis Market Overview
- 15.2. Western Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Relapsing-Remitting Multiple Sclerosis Market
- 16.1. UK Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Relapsing-Remitting Multiple Sclerosis Market
- 17.1. Germany Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Relapsing-Remitting Multiple Sclerosis Market
- 18.1. France Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Relapsing-Remitting Multiple Sclerosis Market
- 19.1. Italy Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Relapsing-Remitting Multiple Sclerosis Market
- 20.1. Spain Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market
- 21.1. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market Overview
- 21.2. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Relapsing-Remitting Multiple Sclerosis Market
- 22.1. Russia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Relapsing-Remitting Multiple Sclerosis Market
- 23.1. North America Relapsing-Remitting Multiple Sclerosis Market Overview
- 23.2. North America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Relapsing-Remitting Multiple Sclerosis Market
- 24.1. USA Relapsing-Remitting Multiple Sclerosis Market Overview
- 24.2. USA Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Relapsing-Remitting Multiple Sclerosis Market
- 25.1. Canada Relapsing-Remitting Multiple Sclerosis Market Overview
- 25.2. Canada Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Relapsing-Remitting Multiple Sclerosis Market
- 26.1. South America Relapsing-Remitting Multiple Sclerosis Market Overview
- 26.2. South America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Relapsing-Remitting Multiple Sclerosis Market
- 27.1. Brazil Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Relapsing-Remitting Multiple Sclerosis Market
- 28.1. Middle East Relapsing-Remitting Multiple Sclerosis Market Overview
- 28.2. Middle East Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Relapsing-Remitting Multiple Sclerosis Market
- 29.1. Africa Relapsing-Remitting Multiple Sclerosis Market Overview
- 29.2. Africa Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Relapsing-Remitting Multiple Sclerosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Relapsing-Remitting Multiple Sclerosis Market Competitive Landscape And Company Profiles
- 30.1. Relapsing-Remitting Multiple Sclerosis Market Competitive Landscape
- 30.2. Relapsing-Remitting Multiple Sclerosis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Relapsing-Remitting Multiple Sclerosis Market Other Major And Innovative Companies
- 31.1. Sanofi S.A.
- 31.2. Bristol-Myers Squibb Company
- 31.3. Novartis AG
- 31.4. GSK plc
- 31.5. Eli Lilly and Company
- 31.6. Merck KGaA
- 31.7. Viatris Inc.
- 31.8. Teva Pharmaceutical Industries Ltd.
- 31.9. Biogen Inc.
- 31.10. Eisai Co. Ltd.
- 31.11. Genentech Inc.
- 31.12. Hikma Pharmaceuticals LLC
- 31.13. Glenmark Pharmaceuticals Limited
- 31.14. CinnaGen Co
- 31.15. Zenas BioPharma Inc.
32. Global Relapsing-Remitting Multiple Sclerosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Relapsing-Remitting Multiple Sclerosis Market
34. Recent Developments In The Relapsing-Remitting Multiple Sclerosis Market
35. Relapsing-Remitting Multiple Sclerosis Market High Potential Countries, Segments and Strategies
- 35.1 Relapsing-Remitting Multiple Sclerosis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Relapsing-Remitting Multiple Sclerosis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Relapsing-Remitting Multiple Sclerosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34947_Relapsing_Remitting_Multiple_Sclerosis_GMR_2025
